Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 481-488, August 2008

Clinical Significance of Troponin I Efflux and Troponin Autoantibodies in Patients With Dilated Cardiomyopathy

  • Kati H. Miettinen, MSc

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
    • Corresponding Author InformationReprint requests: Kati Miettinen, MSC, Kuopio University Hospital, Department of Internal Medicine, P.O. Box 1777, FI-70211 Kuopio, Finland.
  • ,
  • Susann Eriksson, PhD

      Affiliations

    • University of Turku, Turku, Finland
  • ,
  • Jarkko Magga, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Petri Tuomainen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Johanna Kuusisto, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Esko J. Vanninen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Anu Turpeinen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Kari R. Punnonen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland
  • ,
  • Kim Pettersson, PhD

      Affiliations

    • University of Turku, Turku, Finland
  • ,
  • Keijo J. Peuhkurinen, MD, PhD

      Affiliations

    • Kuopio University Hospital and University of Kuopio, Kuopio, Finland

Received 4 June 2007; received in revised form 15 February 2008; accepted 21 February 2008. published online 21 May 2008.

Abstract 

Background

The appearance of circulating autoantibodies against cardiac troponin I (cTnAbs) in patients with heart failure has been reported. We sought to evaluate the role of circulating cardiac troponin I (cTnI) and cTnAbs in the pathophysiology and prognosis of idiopathic dilated cardiomyopathy.

Methods and Results

Circulating concentrations of cTnI and the presence of cTnAbs were determined in 95 patients with idiopathic dilated cardiomyopathy. The patients underwent laboratory testing, echocardiography, cardiopulmonary exercise testing, gated single photon emission computed tomography, and both-sided cardiac catheterization during a 3-day study period. Compared with cTnI− patients, the hearts of cTnI+ patients (cTnI ≥ 0.01 ng/mL, n = 19) were significantly more dilated (left ventricular end-diastolic diameter 67 vs 61 mm, P < .05; left ventricular end-systolic dimension, 55 vs 49 mm, P < .01; echocardiography) and demonstrated greater intracardiac volumes (left ventricular end-diastolic volume 161 vs 132 mL, P = .060; left ventricular end-systolic volume 112 vs 82 mL, P < .05; gated single photon emission computed tomography), more disturbed systolic (ejection fraction 27 vs 33%, P < .05; gated single photon emission computed tomography) and cardiac sympathetic (123I-metaiodobenzylguanidine washout: 41% vs 34%; P < .05) function, and higher levels of vasoactive peptides (N-terminal proatrial natriuretic peptide 1030 vs 558 pmol/L, P < .05; N-terminal pro-B type natriuretic peptide 337 vs 115 pmol/L, P < .05). In addition, during a median follow-up time of 4.1 years, cTnI+ patients had clinical end points (cardiovascular death, heart transplantation, or clinical need for an automatic implantable cardioverter defibrillator) more often than cTnI− patients (37% vs 8%, P < .01). The presence of circulating cTnAbs (n = 15) was not associated with patients' clinical status or outcome.

Conclusion

Patients with idiopathic dilated cardiomyopathy with cTnI efflux demonstrate more prominent changes in the indices of left ventricular remodeling and function than patients without signs of cTnI efflux. Moreover, elevated serum cTnI is associated with poor clinical outcome. The presence of circulating cTnAbs seems to have less utility in the clinical assessment of these patients. However, their pathogenic role in disease progression in the long term cannot be excluded.

Key Words: Autoantibodies, Dilated cardiomyopathy, Outcome, Troponin I

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest statement: Susann Eriksson has a conflict of interest due to recent employment by Innotrac Diagnostics Oy. For the other authors, no conflict of interest exists.

 This study was supported by the Finnish Foundation for Cardiovascular Research, Aarne Koskelo Foundation, Ida Montin Foundation, and The Maud Kuistila Memorial Foundation.

PII: S1071-9164(08)00076-6

doi:10.1016/j.cardfail.2008.02.009

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 481-488, August 2008